白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
4期
193-196
,共4页
王迪%肖敏%朱莉%耿哲%商臻%张娜%刘亚楠%周剑峰%李春蕊
王迪%肖敏%硃莉%耿哲%商臻%張娜%劉亞楠%週劍峰%李春蕊
왕적%초민%주리%경철%상진%장나%류아남%주검봉%리춘예
白血病,非淋巴细胞,急性%基因,NPM1%免疫表型分型
白血病,非淋巴細胞,急性%基因,NPM1%免疫錶型分型
백혈병,비림파세포,급성%기인,NPM1%면역표형분형
Leukemia,nonlymphocytic,acute%Gene,NPM1%Immunophenotyping
目的 研究伴有NPM1基因突变的急性髓系白血病(AML)患者的免疫表型特征.方法 采用流式细胞术检测237例初诊AML患者的免疫表型,并采用实时定量PCR方法对NPM1基因突变进行筛查,比较NPM1突变型和野生型患者的免疫表型差异.结果 NPM1突变型患者占所有AML患者的19.0％(45/237),与野生型相比其CD34、CD117、HLA-DR、CD15、CD19表达降低(均P＜0.05).在正常核型AML患者中,NPM1突变率37.7％(40/106),突变型患者CD34、HLA-DR、CD15和CD7表达降低(均P＜ 0.05).伴NPM1突变的正常核型AML患者的免疫表型在M1中表现为CD34、HLA-DR、CD7表达降低(均P＜ 0.05),在M2中为HLA-DR表达降低和CD9表达升高(均P＜0.05),在M5中为CD117表达降低(P＜0.05).结论 NPM1突变能对AML患者的免疫表型特征造成影响,不同FAB分型的AML患者免疫表型改变存在差异.
目的 研究伴有NPM1基因突變的急性髓繫白血病(AML)患者的免疫錶型特徵.方法 採用流式細胞術檢測237例初診AML患者的免疫錶型,併採用實時定量PCR方法對NPM1基因突變進行篩查,比較NPM1突變型和野生型患者的免疫錶型差異.結果 NPM1突變型患者佔所有AML患者的19.0％(45/237),與野生型相比其CD34、CD117、HLA-DR、CD15、CD19錶達降低(均P＜0.05).在正常覈型AML患者中,NPM1突變率37.7％(40/106),突變型患者CD34、HLA-DR、CD15和CD7錶達降低(均P＜ 0.05).伴NPM1突變的正常覈型AML患者的免疫錶型在M1中錶現為CD34、HLA-DR、CD7錶達降低(均P＜ 0.05),在M2中為HLA-DR錶達降低和CD9錶達升高(均P＜0.05),在M5中為CD117錶達降低(P＜0.05).結論 NPM1突變能對AML患者的免疫錶型特徵造成影響,不同FAB分型的AML患者免疫錶型改變存在差異.
목적 연구반유NPM1기인돌변적급성수계백혈병(AML)환자적면역표형특정.방법 채용류식세포술검측237례초진AML환자적면역표형,병채용실시정량PCR방법대NPM1기인돌변진행사사,비교NPM1돌변형화야생형환자적면역표형차이.결과 NPM1돌변형환자점소유AML환자적19.0％(45/237),여야생형상비기CD34、CD117、HLA-DR、CD15、CD19표체강저(균P＜0.05).재정상핵형AML환자중,NPM1돌변솔37.7％(40/106),돌변형환자CD34、HLA-DR、CD15화CD7표체강저(균P＜ 0.05).반NPM1돌변적정상핵형AML환자적면역표형재M1중표현위CD34、HLA-DR、CD7표체강저(균P＜ 0.05),재M2중위HLA-DR표체강저화CD9표체승고(균P＜0.05),재M5중위CD117표체강저(P＜0.05).결론 NPM1돌변능대AML환자적면역표형특정조성영향,불동FAB분형적AML환자면역표형개변존재차이.
Objective Toinvestigatetheimmunophenotypiccharacteristicsofacutemyeloidleukemia(AML) patients with NPM1 mutation. Methods The immunophenotype of 237 newly diagnosed AML patients were detected by flow cytometry. Real-time quantitative PCR was employed to detect the NPM1 mutation. The immunophenotype was then compared between the NPM1 mutated and wild type patients. Results The incidence of NPM1 mutation was 19.0 ％ (45/237) in all AML patients.The NPM1 mutated patients had lower expression of CD34,CD117,HLA-DR,CD15 and CD19 than the wild type patients(all P＜0.05).For AML patients with normal karyotype,the incidence of NPM1 mutation was 37.7 ％ (40/106),and the NPM1 mutated patients had lower expression of CD34,HLA-DR,CD15 and CD7 than the wild type patients(all P＜0.05).The NPM1 mutated patients with normal karyotype had lower expression of CD34 HLA-DR and CD7 in M1 subtype(all P ＜ 0.05); lower expression of HLA-DR and higher expression of CD9 in M2 subtype (all P ＜ 0.05) ; and lower expression of CD117 in M5 subtype compared with wild type patients (P ＜0.05). Conclusion The immunophenotypic characteristics of AML patients are changed by NPM1 mutation. The changes of immunophenotype varied in different FAB subtypes.
